vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2010-2-74-81vtio-310Research ArticleОбзор литературыLiterature ReviewsПРИМЕНЕНИЕ ЭВЕРОЛИМУСА У DE NOVO РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТАEVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTSПрокопенкоЕ. И.ProkopenkoE. I.ГУ «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского», МоскваРоссияM.F. Vladimirsky Moscow regional clinical research institute, MoscowRussian Federation201005062014122ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XII No 2–20107481Copyright © Прокопенко Е.И., 20102010Прокопенко Е.И.Prokopenko E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/310

В последние годы выживаемость реципиентов ренальных трансплантатов и трансплантированных почек значительно улучшилась, однако долгосрочная выживаемость почечных трансплантатов практически не изменилась. Одним из важнейших факторов развития поздней дисфункции ренального трансплантата яв- ляется нефротоксичность ингибиторов кальциневрина. Эверолимус, новый препарат класса ингибиторов пролиферативного сигнала, позволяет минимизировать экспозицию циклоспорина А, а также обладает противоопухолевым действием. Данная статья представляет собой обзор литературных данных, касаю- щихся клинических аспектов применения эверолимуса у de novo реципиентов ренального трансплантата. 

Survival of renal transplants and renal transplants recipients has improved greatly last years, but long-term graft survival remains unchanged. Nephrotoxicity of calcineurin inhibitors is one of the main factors of late renal allograft disfunction. Everolimus, new proliferation signal inhibitor, can facilitate minimization cyclosporine A exposure and has antineoplastic activity. The paper reviews literature dates regarding to clinical aspects of everolimus use in de novo renal transplant recipients. 

трансплантация почкитоксичность ингибиторов кальциневринаингибиторы пролиферативного сигналаэверолимусrenal transplantationcalcineurin inhibitor toxicityproliferation signal inhibitorseverolimusReferencesANZDATA Registry Report 2004 // Australia and New Zealand Dialysis and Transplant Registry. Ed. McDo- nald S., Excell L. Adelaide, Australia.ANZDATA Registry Report 2004 // Australia and New Zealand Dialysis and Transplant Registry. Ed. McDo- nald S., Excell L. Adelaide, Australia.Bohler T., Waiser J., Budde K. et al. The in vivo effect of rapamycin derivate SDZ RAD on lymphocyte prolifera- tion // Transplant. Proc. 1998. Vol. 30. P. 2195–2197.Bohler T., Waiser J., Budde K. et al. The in vivo effect of rapamycin derivate SDZ RAD on lymphocyte prolifera- tion // Transplant. Proc. 1998. Vol. 30. P. 2195–2197.Budde K., Lehne G., Winkler M. et al. Influence of ever- olimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients // J. Clin. Phar- macol. 2005. Vol. 45(7). P. 781–791.Budde K., Lehne G., Winkler M. et al. Influence of ever- olimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients // J. Clin. Phar- macol. 2005. Vol. 45(7). P. 781–791.Certican® Summary of Product Characteristics, 2006.Certican® Summary of Product Characteristics, 2006.Cоhen B., Smits J.M., Haase B. et al. Expanding the donor pool to increase renal transplantation // Nephrol.Cоhen B., Smits J.M., Haase B. et al. Expanding the donor pool to increase renal transplantation // Nephrol.Dial. Transplant. 2005. Vol. 20. P. 34–41.Dial. Transplant. 2005. Vol. 20. P. 34–41.Fritsche L., Horstrup J., Budde K. et al. Old-for-old kid- ney allocation allows successful expansion of the donor and recipient pool // Am. J. Transplant. 2003. Vol. 3.Fritsche L., Horstrup J., Budde K. et al. Old-for-old kid- ney allocation allows successful expansion of the donor and recipient pool // Am. J. Transplant. 2003. Vol. 3.P. 1434–1438.P. 1434–1438.Goudar R.K., Shi Q., Hjelmeland M.D. et al. CombinationGoudar R.K., Shi Q., Hjelmeland M.D. et al. Combinationtherapy of inhibitors of epidermal growth factor receptor/ vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) of- fers improved glioblastoma tumor growth inhibition // Mol. Cancer. Ther. 2005. Vol. 4. P. 101–112.therapy of inhibitors of epidermal growth factor receptor/ vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) of- fers improved glioblastoma tumor growth inhibition // Mol. Cancer. Ther. 2005. Vol. 4. P. 101–112.Hoyer P.F., Ettenger R., Kovarik J.M. et al. Everolimus in pediatric de novo renal transplant patients // Trans- plantation. 2003. Vol. 75. P. 2082–2085.Hoyer P.F., Ettenger R., Kovarik J.M. et al. Everolimus in pediatric de novo renal transplant patients // Trans- plantation. 2003. Vol. 75. P. 2082–2085.Kauffman H.M., Cherikh W.S., Cheng Y. et al. Main- tenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies// Transplantation. 2005. Vol.80. P. 883–889.Kauffman H.M., Cherikh W.S., Cheng Y. et al. Main- tenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies// Transplantation. 2005. Vol.80. P. 883–889.Keown P. Improving quality of life. The new target for transplantation // Transplantation. 2001. Vol. 72 (12). P. S67–74.Keown P. Improving quality of life. The new target for transplantation // Transplantation. 2001. Vol. 72 (12). P. S67–74.Kirchner I.G., Meier-Wiedenbach I., Manns M.P. Clini- cal pharmacokinetics of everolimus // Clin. Pharmacol. 2004. Vol. 43 (2). P. 83–95.Kirchner I.G., Meier-Wiedenbach I., Manns M.P. Clini- cal pharmacokinetics of everolimus // Clin. Pharmacol. 2004. Vol. 43 (2). P. 83–95.Kolhe N., Mamode N., Van der Walt J., Pattison J. Re- gression of post-transplant Kaposi’s sarcoma using siro- limus // Int. J. Clin. Pract. 2006. Vol. 60 (11). P. 1509– 1512.Kolhe N., Mamode N., Van der Walt J., Pattison J. Re- gression of post-transplant Kaposi’s sarcoma using siro- limus // Int. J. Clin. Pract. 2006. Vol. 60 (11). P. 1509– 1512.Kovaric J.M., Curtis J.J., Hricik D.E. et al. Differential pharmacokinetic interaction of tacrolimus and cyclo- sporine on everolimus // Transplant. Proc. 2006. Vol. 38 (10). P. 3456–3458.Kovaric J.M., Curtis J.J., Hricik D.E. et al. Differential pharmacokinetic interaction of tacrolimus and cyclo- sporine on everolimus // Transplant. Proc. 2006. Vol. 38 (10). P. 3456–3458.Kovaric J.M., Kahan B.D., Kaplan B. et al. Longitudinal assessment of everolimus in de novo renal transplant re- cipients over the first post-transplant year: pharmacoki- netics, exposure-response relationships, and influenceKovaric J.M., Kahan B.D., Kaplan B. et al. Longitudinal assessment of everolimus in de novo renal transplant re- cipients over the first post-transplant year: pharmacoki- netics, exposure-response relationships, and influenceon cyclosporine // Clin. Pharmacol. Ther. 2001. Vol. 69.on cyclosporine // Clin. Pharmacol. Ther. 2001. Vol. 69.P. 48–56.P. 48–56.Kovaric J.M., Kalbag J., Figueiredo J. et al. DifferentialKovaric J.M., Kalbag J., Figueiredo J. et al. Differentialinfluence of two cyclosporine formulations on everoli- mus pharmacokinetics: a clinically relevant pharmacoki- netic interaction // J. Clin. Pharmacol. 2002. Vol. 42. P. 95–99.influence of two cyclosporine formulations on everoli- mus pharmacokinetics: a clinically relevant pharmacoki- netic interaction // J. Clin. Pharmacol. 2002. Vol. 42. P. 95–99.Krieger N.R., Becker B.N., Heisey D.M. et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related and living-unre- lated grafts // Transplantation. 2003. Vol. 75. P. 1677– 1682.Krieger N.R., Becker B.N., Heisey D.M. et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related and living-unre- lated grafts // Transplantation. 2003. Vol. 75. P. 1677– 1682.Lebbé C., Euvrard S., Barrou B. et al. Sirolimus conver- sion for patients with posttransplant Kaposi’s sarcoma // Am. J. Transplant. 2006. Vol. 6 (9). P. 2164–2168.Lebbé C., Euvrard S., Barrou B. et al. Sirolimus conver- sion for patients with posttransplant Kaposi’s sarcoma // Am. J. Transplant. 2006. Vol. 6 (9). P. 2164–2168.Lorber M.I., Mulgaonkar S., Butt K.M.H. et al. Everoli- mus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study // Transplanta- tion. 2005. Vol. 80. P. 244–252.Lorber M.I., Mulgaonkar S., Butt K.M.H. et al. Everoli- mus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study // Transplanta- tion. 2005. Vol. 80. P. 244–252.Lorber M.I., Ponticelli C., Whelchel J. et al. Therapeutic drug monitoring for everolimus in kidney transplanta- tion using 12-month exposure, efficacy and safety data // Clin. Transplant. 2005. Vol. 19. P. 145–152.Lorber M.I., Ponticelli C., Whelchel J. et al. Therapeutic drug monitoring for everolimus in kidney transplanta- tion using 12-month exposure, efficacy and safety data // Clin. Transplant. 2005. Vol. 19. P. 145–152.Majewski M., Korecka M., Joergensen J. et al. Immu- nosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting do- ses // Transplantation. 2003. Vol. 75. P. 1710–1717.Majewski M., Korecka M., Joergensen J. et al. Immu- nosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting do- ses // Transplantation. 2003. Vol. 75. P. 1710–1717.Majewski M., Korecka M., Kossev P. et al. The immuno- suppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and tre- atment of posttransplant lymphoproliferative disorders // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 4285– 4290.Majewski M., Korecka M., Kossev P. et al. The immuno- suppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and tre- atment of posttransplant lymphoproliferative disorders // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 4285– 4290.Majumder P.K., Febbo P.G., Bikoff R. et al. mTOR in- hibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1- dependent pathways // Nat. Med. 2004. Vol. 10. P. 594– 601.Majumder P.K., Febbo P.G., Bikoff R. et al. mTOR in- hibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1- dependent pathways // Nat. Med. 2004. Vol. 10. P. 594– 601.Meier-Kriesche H.U., Schold J.D., Kaplan B. Long- term renal allograft survival: have we made significant progress or is it time to rethink our analytic and thera- peutic strategies? // Am. J. Transplant. 2004. Vol. 4 (8). P. 1289–1295.Meier-Kriesche H.U., Schold J.D., Kaplan B. Long- term renal allograft survival: have we made significant progress or is it time to rethink our analytic and thera- peutic strategies? // Am. J. Transplant. 2004. Vol. 4 (8). P. 1289–1295.Morrissey P.E., Gohh R., Yango A. et al. Renal transplant survival from older donors: a single center experience // Arch. Surg. 2004. Vol. 139. P. 384–389.Morrissey P.E., Gohh R., Yango A. et al. Renal transplant survival from older donors: a single center experience // Arch. Surg. 2004. Vol. 139. P. 384–389.Nankivell B.J., Borrows R.J., Fung C.L. et al. The natu- ral history of chronic allograft nephropathy // N. Engl. J. Med. 2003. Vol. 349. P. 2326–2333.Nankivell B.J., Borrows R.J., Fung C.L. et al. The natu- ral history of chronic allograft nephropathy // N. Engl. J. Med. 2003. Vol. 349. P. 2326–2333.Nashan B. The role of Certican (everolimus, RAD) in the many pathways of chronic rejection // Transplant. Proc. 2001. Vol. 33. P. 3215–3220.Nashan B. The role of Certican (everolimus, RAD) in the many pathways of chronic rejection // Transplant. Proc. 2001. Vol. 33. P. 3215–3220.Nashan B., Curtis J.J., Ponticelli C. et al. Everolimus and reduced-exposure cyclosporine in de novo renal- transplant recipients: a three-year phase II, randomized, multicenter, open-label study // Transplantation. 2004. Vol. 78. P. 1332–1340.Nashan B., Curtis J.J., Ponticelli C. et al. Everolimus and reduced-exposure cyclosporine in de novo renal- transplant recipients: a three-year phase II, randomized, multicenter, open-label study // Transplantation. 2004. Vol. 78. P. 1332–1340.Pascual J., Boletis I.N., Campistol J.M. Everolimus (Certican®) in renal transplantation: a review of trial data, current usage and future directions // Transplant. Rev. 2006. Vol. 20. P. 1–18.Pascual J., Boletis I.N., Campistol J.M. Everolimus (Certican®) in renal transplantation: a review of trial data, current usage and future directions // Transplant. Rev. 2006. Vol. 20. P. 1–18.Pascual J., Cambi V., Dissegna D. et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients: 24 month analysis // Am. J. Transplant. 2005. Vol. 5 (Suppl. 11). Р. A1010.Pascual J., Cambi V., Dissegna D. et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral in de novo kidney transplant recipients: 24 month analysis // Am. J. Transplant. 2005. Vol. 5 (Suppl. 11). Р. A1010.Pascual J., Marcen R., Ortuno J. Clinical experience with everolimus (Certican) in elderly recipients: the «old-for-old» concept // Transplantation. 2005. Vol. 79. P. S85–S88.Pascual J., Marcen R., Ortuno J. Clinical experience with everolimus (Certican) in elderly recipients: the «old-for-old» concept // Transplantation. 2005. Vol. 79. P. S85–S88.Ponticelli C. Reducing exposure to calcineurin inhibitors following renal transplantation: clinical experience with everolimus (Certican) // Transplantation. 2005. Vol. 79. P. S69–S71.Ponticelli C. Reducing exposure to calcineurin inhibitors following renal transplantation: clinical experience with everolimus (Certican) // Transplantation. 2005. Vol. 79. P. S69–S71.Racusen L.C., Solez K., Colvin R.B. Fibrosis and atrophy in the renal allograft: interim report and new directions // Am. J. Transplant. 2002. Vol. 2. P. 203–206.Racusen L.C., Solez K., Colvin R.B. Fibrosis and atrophy in the renal allograft: interim report and new directions // Am. J. Transplant. 2002. Vol. 2. P. 203–206.Rapamune® Summary of Product Characteristics, 2007.Rapamune® Summary of Product Characteristics, 2007.Schuurman H.J., Cotton S., Fuchs S. et al. SDZ RAD, a new rapamycin derivate: Synergism with cyclosporine //Schuurman H.J., Cotton S., Fuchs S. et al. SDZ RAD, a new rapamycin derivate: Synergism with cyclosporine //Transplantation. 1997. Vol. 64. P. 32–35.Transplantation. 1997. Vol. 64. P. 32–35.Schuurman J.J., Ringers J., Schuler W. et al. Oral effica-Schuurman J.J., Ringers J., Schuler W. et al. Oral effica-cy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney transplantation // Transplantation. 2000. Vol. 69. P. 737–742.cy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney transplantation // Transplantation. 2000. Vol. 69. P. 737–742.Serkova N., Jacobsen W., Niemann C.U. et al. Siroli- mus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mito- chondrial metabolism in the rat brain // Br. J. Pharmacol. 2001. Vol. 133. P. 875–885.Serkova N., Jacobsen W., Niemann C.U. et al. Siroli- mus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mito- chondrial metabolism in the rat brain // Br. J. Pharmacol. 2001. Vol. 133. P. 875–885.Serkova N., Litt L., James T.L. et al. Evaluation of indivi- dual and combined neurotoxicity of the immunosuppres-Serkova N., Litt L., James T.L. et al. Evaluation of indivi- dual and combined neurotoxicity of the immunosuppres-sants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy // J. Pharmacol. Exp. Ther. 1999. Vol. 289. P. 800–806.sants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy // J. Pharmacol. Exp. Ther. 1999. Vol. 289. P. 800–806.Serkova N., Litt L., Leibfritz D. et al. The novel immu- nosuppressant SDZ RAD protect rat brain slices from cyclosporine-induced reduction of high-energy phos- phates // Br. J. Pharmacol. 2000. Vol. 129. P. 485–492.Serkova N., Litt L., Leibfritz D. et al. The novel immu- nosuppressant SDZ RAD protect rat brain slices from cyclosporine-induced reduction of high-energy phos- phates // Br. J. Pharmacol. 2000. Vol. 129. P. 485–492.Smits J.M., Persijn G.G., van Houwelingen H.C. et al. Evaluation of the Eurotransplant Senior Program. The results of the first year // Am. J. Transplant. 2002. Vol. 2. P. 664–670.Smits J.M., Persijn G.G., van Houwelingen H.C. et al. Evaluation of the Eurotransplant Senior Program. The results of the first year // Am. J. Transplant. 2002. Vol. 2. P. 664–670.Stallone G., Schena A., Infante B. et al. Sirolimus for Ka- posi’s sarcoma in renal-transplant recipients // N. Engl. J. Med. 2005. Vol. 352 (13). P. 1317–1323.Stallone G., Schena A., Infante B. et al. Sirolimus for Ka- posi’s sarcoma in renal-transplant recipients // N. Engl. J. Med. 2005. Vol. 352 (13). P. 1317–1323.Tedesco-Silva H. Jr., Vitko S., Pascual J. et al. 2306 and 2307 study groups. 12-month safety and efficacy of ever- olimus with reduced exposure cyclosporine in de novo renal transplant recipients // Transpl. Int. 2007. Vol. 20 (1). P. 27–36.Tedesco-Silva H. Jr., Vitko S., Pascual J. et al. 2306 and 2307 study groups. 12-month safety and efficacy of ever- olimus with reduced exposure cyclosporine in de novo renal transplant recipients // Transpl. Int. 2007. Vol. 20 (1). P. 27–36.Vitko S., Margreiter R., Weimar W. et al. Everolimus (Certican) 12-month safety and efficacy versus myco- phenolate mofetil in de novo renal transplant recipients // Transplantation. 2004. Vol. 78. P. 1532–1540.Vitko S., Margreiter R., Weimar W. et al. Everolimus (Certican) 12-month safety and efficacy versus myco- phenolate mofetil in de novo renal transplant recipients // Transplantation. 2004. Vol. 78. P. 1532–1540.Vitko S., Margreiter R., Weimar W. et al. Three-year effi- cacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant pa- tients // Am. J. Transplant. 2005. Vol. 5. P. 2521–2530.Vitko S., Margreiter R., Weimar W. et al. Three-year effi- cacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant pa- tients // Am. J. Transplant. 2005. Vol. 5. P. 2521–2530.Vitko S., Tedesco H., Eris J. et al. Everolimus with opti- mized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies // Am. J. Transplant. 2004. Vol. 4. P. 626–635.Vitko S., Tedesco H., Eris J. et al. Everolimus with opti- mized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies // Am. J. Transplant. 2004. Vol. 4. P. 626–635.Wolfe R.A., Ashby V.B., Milford E.L. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cada- veric transplant // N. Engl. J. Med. 1999. Vol. 341 (23). P. 1725–1730.Wolfe R.A., Ashby V.B., Milford E.L. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cada- veric transplant // N. Engl. J. Med. 1999. Vol. 341 (23). P. 1725–1730.

The authors declare that there are no conflicts of interest present.